Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25479
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiva, Aksel-
dc.contributor.authorErtaş, Mustafa-
dc.contributor.authorSaip, Sabahattin-
dc.contributor.authorBaykal, Betül-
dc.contributor.authorKeskinaslan, Abdulkadir-
dc.contributor.authorŞenocak, Mustafa Şükrü-
dc.date.accessioned2022-03-31T07:39:20Z-
dc.date.available2022-03-31T07:39:20Z-
dc.date.issued2008-04-15-
dc.identifier.citationSiva, A. vd. (2008). "Validity of the ID-Migraine screener in the workplace". Neurology, 70(16), 1337-1345.en_US
dc.identifier.issn0028-3878-
dc.identifier.issn18413587-
dc.identifier.urihttps://doi.org/10.1212/01.wnl.0000309221.85545.0d-
dc.identifier.urihttps://n.neurology.org/content/70/16/1337-
dc.identifier.urihttp://hdl.handle.net/11452/25479-
dc.description.abstractObjective: The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener ( ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. Methods: A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition ( ICHD-2) criteria. Results: A total of 227 subjects ( mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects ( 46.7%) according to the ID-Ms and in 117 of the 227 subjects ( 51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. Conclusion: The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.en_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectQuality-of-lifeen_US
dc.subjectAssessment midas questionnaireen_US
dc.subjectUnited-statesen_US
dc.subjectGeneral-populationen_US
dc.subjectYoung-adultsen_US
dc.subjectDisabilityen_US
dc.subjectHeadacheen_US
dc.subjectBurdenen_US
dc.subjectImpacten_US
dc.subjectPrevalenceen_US
dc.subjectNeurosciences & neurologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshFemaleen_US
dc.subject.meshHealth surveysen_US
dc.subject.meshHumansen_US
dc.subject.meshIndustryen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMigraine disordersen_US
dc.subject.meshPain measurementen_US
dc.subject.meshTurkeyen_US
dc.subject.meshWorkplaceen_US
dc.titleValidity of the ID-migraine screener in the workplaceen_US
dc.typeArticleen_US
dc.identifier.wos000256706600007tr_TR
dc.identifier.scopus2-s2.0-42249101751tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.identifier.startpage1337tr_TR
dc.identifier.endpage1345tr_TR
dc.identifier.volume70tr_TR
dc.identifier.issue16tr_TR
dc.relation.journalNeurologyen_US
dc.contributor.buuauthorZarifoğlu, Mehmet-
dc.contributor.buuauthorKarlı, Hamdi Necdet-
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed18413587tr_TR
dc.subject.wosClinical neurologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ1en_US
dc.contributor.scopusid6603411305tr_TR
dc.contributor.scopusid57193973560tr_TR
dc.subject.scopusMigraine Disorders; Headache; Tryptaminesen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeEmployeeen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMigraineen_US
dc.subject.emtreemaleen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProductivityen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeScreening testen_US
dc.subject.emtreeSensitivity and specificityen_US
dc.subject.emtreeShort Form 36en_US
dc.subject.emtreeValidityen_US
dc.subject.emtreeWork disabilityen_US
dc.subject.emtreeWorkplaceen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.